Results 101 to 110 of about 45,216 (237)
Hypoxic 3D in vitro culture models reveal distinct resistance processes to TKIs in renal cancer cells [PDF]
, 2012 The aim of this study is to determine the effect of hypoxia on axitinib and sorafenib-treated renal cell carcinoma (RCC) cells. Hypoxia is a crucial factor influencing transcription process via protein modulation, which was shown i.e.
Bielecka, Zofia +9 more
core +6 more sources
International Journal of Cancer, EarlyView.Abstract Hepatocellular carcinoma (HCC) represents the predominant form of primary liver cancer and is frequently identified at a late stage, necessitating systemic therapy. However, resistance to first‐line tyrosine kinase inhibitor therapies, such as sorafenib and lenvatinib, remains a significant clinical challenge.
Longtao Zhao +6 more
wiley +1 more source
Inhibition of pMAPK14 Overcomes Resistance to Sorafenib in Hepatoma Cells with Hepatitis B Virus
Translational Oncology, 2018 Hepatitis B virus (HBV) targets the liver and is a major driver for liver cancer. Clinical data suggest that HBV infection is associated with reduced response to treatment with the multi-kinase inhibitor sorafenib, the first available molecularly ...
Dvora Witt-Kehati +4 more
doaj +1 more source
Focal adhesion kinase: Insight into molecular roles and functions in hepatocellular carcinoma [PDF]
, 2017 Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. Due to the high incidence of post-operative recurrence after current treatments, the identification of new and more effective drugs is required.
Alisi, Anna +4 more
core +2 more sources
International Journal of Cancer, EarlyView.What's New? Most patients with ovarian cancer (OC) relapse after first‐line chemotherapy, and prognosis with second‐line treatment depends largely on the platinum‐free interval. However, reliable biomarkers to predict response to second‐line therapy remain lacking.
Muhammad Habiburrahman +7 more
wiley +1 more source
Frontiers in ImmunologyIntroductionSorafenib is currently the first-line treatment for patients with advanced hepatocellular carcinoma (HCC). Nevertheless, sorafenib resistance remains a huge challenge in the clinic.
Junzhang Chen +4 more
doaj +1 more source
Multiple Roles of Autophagy in the Sorafenib Resistance of Hepatocellular Carcinoma
Cellular Physiology and Biochemistry, 2017 Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide, and prognosis remains unsatisfactory since the disease is often diagnosed at the advanced stages.
Ting Sun, Hongchun Liu, Liang Ming
doaj +1 more source
Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study. [PDF]
, 2017 BackgroundCabozantinib, an orally bioavailable inhibitor of tyrosine kinases including MET, AXL, and VEGF receptors, was assessed in patients with hepatocellular carcinoma (HCC) as part of a phase 2 randomized discontinuation trial with nine tumor-type ...
Braiteh, F +11 more
core
The paradox of cancer genes in non-malignant conditions: implications for precision medicine. [PDF]
, 2020 Next-generation sequencing has enabled patient selection for targeted drugs, some of which have shown remarkable efficacy in cancers that have the cognate molecular signatures.
Adashek, Jacob J +3 more
core
Relationship and predictive role of the dual expression of FGFR and IL-8 in metastatic renal cell carcinoma treated with targeted agents [PDF]
, 2018 Background/Aim: The expression of IL-8 and FGFR has been related to prognosis and pathological features in renal cell carcinoma. We investigated the relationship between IL-8 and FGFR and the outcome in metastatic renal cell carcinoma (mRCC) patients ...
Carella, Consiglia +7 more
core +1 more source